 Secondary endpoints are changes from baseline in glycemic profiles HbA1c, Glycated albumin, Lipid parameters Total Cholesterol, Triglycerides, HDL-C, LDL-C, Liver function parameters AST, ALT, r-GT, and adverse events during the trial. 